Yusra Shao, M.D.

Specialties

Oncology - Medical

Board Certification

American Board of Internal Medicine

Multidisciplinary Team

Language(s) Spoken

English, Gujarati, Hindi, Urdu

Locations

Karmanos Cancer Center
4100 John R
Detroit, MI 48201
Get Directions

Phone:1-800-KARMANOS

Call For Appointment

Podcast: Listen

Cancers Treatments

Locations

Karmanos Cancer Center

4100 John R
Detroit, MI 48201
Get Directions

Phone:1-800-KARMANOS

Get Directions

Education

Cancers Treatments

Clinical Trials

A Phase II Randomized Trial of Cabozantinib (NSC #761968) With or Without Atezolizumab (NSC #783608) in Patients With Advanced Papillary Renal Cell Carcinoma (PAPMET2)

Cancer Category
Genitourinary (GU)
Age Group
Adult
Phase
Phase II

A Phase 3 Trial of Fianlimab (Anti-LAG-3) and Cemiplimab Versus Pembrolizumab in the Adjuvant Setting in Patients With Completely Resected High-risk Melanoma

Cancer Category
Skin
Age Group
Adult
Phase
Phase III

A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab Versus Relatlimab and Nivolumab in Participants with Unresectable or Metastatic Melanoma

Cancer Category
Skin
Age Group
Adult
Phase
Phase III

A Randomized, Open-label Phase 3 Study in Patients With Previously Treated Unresectable or Metastatic NRAS Mutant Cutaneous Melanoma Comparing the Combination of Naporafenib + Trametinib to Physician's Choice of Therapy (Dacarbazine, Temozolomide or Tramet

Cancer Category
Skin
Age Group
Adult
Phase
Phase III

A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC-7366 in Combination with Belzutifan (WELIREGTM) in Subjects with Locally Advanced (Inoperable) or Metastatic Renal Cell Carcinoma

Cancer Category
Genitourinary (GU)
Age Group
Adult
Phase
Phase I

A first-in-human, Phase 1/2, open-label, multi-center, dose-escalation, dose-optimization, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of PARP1 selective inhibitor, IMP1734, in

Cancer Category
Breast,Gastrointestinal (GI),Gynecologic
Age Group
Adult
Phase
Phase I/II

A Phase 3, multicenter, randomized, open-label, parallel group, treatment study to assess the efficacy and safety of the lifileucel (LN-144, autologous tumor-infiltrating lymphocytes [TIL]) regimen in combination with pembrolizumab compared with pembrolizu

Cancer Category
Skin
Age Group
Adult
Phase
Phase III

An Open-label, Multicenter Study of LOXO-435 (LY3866288) in Advanced Solid Tumor Malignancies with FGFR3 Alterations

Cancer Category
Genitourinary (GU),Gynecologic
Age Group
Adult
Phase
Phase I

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors

Cancer Category
Genitourinary (GU)
Age Group
Adult
Phase
Phase I

A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone or in Combination with Pembrolizumab in Subjects with Locally Advanced Unresectable or Metastatic Urothelial Carcinoma

Cancer Category
Genitourinary (GU)
Age Group
Adult
Phase
Phase II

Additional Info

Yusra F. Shao, M.D., is a recent graduate of the Hematology and Oncology fellowship at Karmanos Cancer Institute/Wayne State University where she served as chief fellow. Dr. Shao has a niche research interest in ocular melanoma and developing immune and cellular therapies. She is a member of the Cutaneous and Genitourinary Precision Oncology Alliance, and continues to publish and present her research work nationally. Dr. Shao is also passionate about promoting access to oncologic care to the underserved populations of the Detroit Metropolitan Area through her community outreach work. In her leisure time, she enjoys painting and exploring the outdoors.

Related News

September 05, 2024
IN THE NEWS: Dr. Yusra Shao and Meltdown Talk About Prostate Cancer Screening

101 WRIF Yusra Shao, M.D. , medical oncologist and member of the Genitourinary Oncology Multidisciplinary Team at Karmanos, talks to Meltdown from 101 WRIF about prostate cancer. They discuss when me should start talking to their primary care provider about prostate cancer screening. For more information, go to karmanos.org/prostatefacts . Your browser does not support the audio element. Download Podcast
Read More
May 08, 2024
IN THE NEWS: How Fast Does Bladder Cancer Spread?

Patient Power It’s estimated that about 4% of cancers that will be diagnosed in 2024 will be bladder cancer. Yusra Shao, M.D. , medical oncologist and member of the Genitourinary Oncology Multidisciplinary Team at Karmanos, explained what physicians do to determine whether bladder cancer has spread to other areas of the body and the signs and symptoms of the disease. Read the article here .
Read More
April 03, 2024
IN THE NEWS: Can You Drink Coffee While Taking Prednisone?

The Checkup by SingleCare Coffee has its benefits, but if taking other medications, it's vital to know if adding a cup of Joe might cause side effects. Yusra Shao, M.D. , medical oncologist and member of the Genitourinary Oncology , Melanoma , and Phase 1 Clinical Trials Multidisciplinary Teams at the Barbara Ann Karmanos Cancer Institute , sometimes prescribes prednisone, a steroid, to her patients. Jelena Radan, Pharm.D., BCPS, lead clinical pharmacy specialist at KSP Specialty Pharmacy , and Dr. Shao...
Read More

Publications

Shao YF, DeBenedictis M, Yeaney G, Singh AD. Germ line BAP1 Mutation in Patients with Uveal Melanoma (UM) and Renal Cell Carcinoma (RCC). Ocular Oncology and Pathology 2021; 7:340–345 PMID: 34722490
Shao YF, Echegaray JJ, Singh N, Singh AD. Variability of Bad Prognosis in Uveal Melanoma. Ophthalmology Retina 2019
186–193. PMID: 31014770 3. Brewington BY, Shao YF, Davidorf FH, Cebulla CM. Brachytherapy for Patients with Uveal Melanoma: Historical Perspectives and Future Treatment Directions. Clinical Ophthalmology 2018; 12, 925–934. PMID: 29844657
Nagasaka M, Al-Share B, Shao YF, Sexton R, Al Hallak MN, Azmi AS, Sukari A. The Gut Microbiome and Cancer: A Comprehensive Review of Melanoma, Lung, Head and Neck and Gastrointestinal Tumors. Reference Collection in Food Science (planned for publication in the Comprehensive Gut Microbiota) Elsevier. Equal contribution as first author
Shao YF, Echegaray JJ, Singh AD. Metastatic Tumors of the Uvea. Intraocular Tumors 179–185 (Springer Singapore, 2019)

Provider Profile:
Yusra Shao, M.D.

Yusra Shao, M.D.

Cancers Treated

Locations

Karmanos Cancer Center

Education

School

Residency

Fellowships

Clinical Trials

A Phase II Randomized Trial of Cabozantinib (NSC #761968) With or Without Atezolizumab (NSC #783608) in Patients With Advanced Papillary Renal Cell Carcinoma (PAPMET2)

A Phase 3 Trial of Fianlimab (Anti-LAG-3) and Cemiplimab Versus Pembrolizumab in the Adjuvant Setting in Patients With Completely Resected High-risk Melanoma

A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab Versus Relatlimab and Nivolumab in Participants with Unresectable or Metastatic Melanoma

A Randomized, Open-label Phase 3 Study in Patients With Previously Treated Unresectable or Metastatic NRAS Mutant Cutaneous Melanoma Comparing the Combination of Naporafenib + Trametinib to Physician's Choice of Therapy (Dacarbazine, Temozolomide or Tramet

A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC-7366 in Combination with Belzutifan (WELIREGTM) in Subjects with Locally Advanced (Inoperable) or Metastatic Renal Cell Carcinoma

A first-in-human, Phase 1/2, open-label, multi-center, dose-escalation, dose-optimization, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of PARP1 selective inhibitor, IMP1734, in

A Phase 3, multicenter, randomized, open-label, parallel group, treatment study to assess the efficacy and safety of the lifileucel (LN-144, autologous tumor-infiltrating lymphocytes [TIL]) regimen in combination with pembrolizumab compared with pembrolizu

An Open-label, Multicenter Study of LOXO-435 (LY3866288) in Advanced Solid Tumor Malignancies with FGFR3 Alterations

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors

A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone or in Combination with Pembrolizumab in Subjects with Locally Advanced Unresectable or Metastatic Urothelial Carcinoma

Additional Info

Related News

IN THE NEWS: Dr. Yusra Shao and Meltdown Talk About Prostate Cancer Screening

IN THE NEWS: How Fast Does Bladder Cancer Spread?

IN THE NEWS: Can You Drink Coffee While Taking Prednisone?

WRIF | Dr. Yusra Shao and Meltdown Talk About Prostate Cancer Screening

Publications

Provider Profile: Yusra Shao, M.D.

Yusra Shao, M.D.

Locations

Karmanos Cancer Center

Provider Profile:
Yusra Shao, M.D.